Soleil Boughton Sells 9,463 Shares of Hims & Hers Health (NYSE:HIMS) Stock

24 Apr 2026, 09:20 by Tristan Rich · The Markets Daily

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Soleil Boughton sold 9,463 shares of the business’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of $30.00, for a total transaction of $283,890.00. Following the sale, the insider owned 299,368 shares in the company, valued at $8,981,040. This trade represents a 3.06% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

On Tuesday, March 17th, Soleil Boughton sold 4,812 shares of Hims & Hers Health stock. The stock was sold at an average price of $24.69, for a total transaction of $118,808.28.

Hims & Hers Health Stock Down 2.9%

Shares of NYSE:HIMS opened at $28.16 on Friday. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The firm has a market capitalization of $6.42 billion, a PE ratio of 55.22, a price-to-earnings-growth ratio of 2.75 and a beta of 2.32. The firm’s 50-day moving average is $20.70 and its two-hundred day moving average is $31.71. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. The company had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.11 earnings per share. Analysts predict that Hims & Hers Health, Inc. will post 0.61 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on HIMS. Bank of America upped their target price on shares of Hims & Hers Health from $21.00 to $25.00 and gave the stock a “neutral” rating in a research note on Thursday, April 16th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Evercore set a $24.00 target price on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Finally, TD Cowen cut their target price on shares of Hims & Hers Health from $25.00 to $23.00 and set a “hold” rating on the stock in a research note on Friday, March 27th. Three investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $31.86.

Check Out Our Latest Stock Analysis on Hims & Hers Health

Hedge Funds Weigh In On Hims & Hers Health

Several hedge funds have recently added to or reduced their stakes in HIMS. VIRGINIA RETIREMENT SYSTEMS ET Al boosted its holdings in shares of Hims & Hers Health by 0.8% in the third quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 25,600 shares of the company’s stock valued at $1,452,000 after acquiring an additional 200 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Hims & Hers Health by 6.1% in the third quarter. GAMMA Investing LLC now owns 4,098 shares of the company’s stock valued at $232,000 after acquiring an additional 236 shares during the period. Concurrent Investment Advisors LLC boosted its holdings in shares of Hims & Hers Health by 1.8% in the third quarter. Concurrent Investment Advisors LLC now owns 13,984 shares of the company’s stock valued at $793,000 after acquiring an additional 252 shares during the period. Smartleaf Asset Management LLC boosted its holdings in shares of Hims & Hers Health by 44.7% in the third quarter. Smartleaf Asset Management LLC now owns 916 shares of the company’s stock valued at $54,000 after acquiring an additional 283 shares during the period. Finally, W.G. Shaheen & Associates DBA Whitney & Co boosted its holdings in shares of Hims & Hers Health by 4.8% in the third quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 7,695 shares of the company’s stock valued at $436,000 after acquiring an additional 350 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Expanded Eli Lilly tie‑in — HIMS said clinicians on its platform can now prescribe several Lilly weight‑loss formats (Zepbound vials, KwikPen, Foundayo) with fulfillment via LillyDirect, which initially pushed the stock higher as investors priced direct access to GLP‑1 demand. Hims & Hers Jumps On Its New Eli Lilly-Tied Approach To Obesity
Positive Sentiment: Product expansion into menopause care — HIMS added perimenopause/menopause treatment options (including estrogen‑patch access) to its telehealth platform, widening recurring care use cases and the addressable market beyond weight‑loss. Hims & Hers expands into menopause care as estrogen patch demand rises
Neutral Sentiment: Regulatory / pipeline chatter — Markets have reacted to a reported FDA “win” and peptide‑pipeline speculation that traders view as optional upside; analysts warn some of this may already be priced in. Hims & Hers (HIMS) Gets Good News from the FDA
Neutral Sentiment: Sector flow / analyst backdrop — Broader GLP‑1 and telehealth momentum has amplified HIMS moves; coverage remains mixed (consensus “Hold”), so swings may be driven more by sentiment and flows than fresh fundamentals. Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term
Negative Sentiment: Profit‑taking and reversal after initial pop — After the Lilly announcement lifted the stock, a follow‑up note flagged doubts about the new obesity plan and execution, triggering a reversal. That intraday giveback pressured sentiment. Hims & Hers Reverses Amid Doubts About Its Newest Obesity Plan
Negative Sentiment: Insider selling — Multiple filings show sizable 10b5‑1 sales by the CFO and other insiders in April; while planned sales reduce informational signal, the volume can weigh on near‑term stock sentiment. SEC filing (Okupe sale) SEC filing (Soleil Boughton sale)
Negative Sentiment: Competition risk — New, deep‑pocketed entrants (Amazon’s GLP‑1 program) amplify concerns about margin pressure and customer share loss in HIMS’ high‑value weight‑loss channel. Amazon unveils competing weight-loss program

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.